Table 1 Sociodemographic and symptom related characteristics of the total sample and the four subsamples
Variable | Total sample n = 381 n (%) /M ± SD | Sample without migration background n = 194 n (%) /M ± SD | Sample with Turkish migration background n = 111 n (%) /M ± SD | Sample with East European migration background n = 39 n (%) /M ± SD | Sample with MENAP migration background n = 37 n (%) /M ± SD | p-value |
|---|---|---|---|---|---|---|
Gender | ||||||
 female | 224 (58.8) | 100 (51.6) | 85 (76.6) | 21 (53.9) | 18 (48.6) | < .001* |
 male | 157 (41.2) | 94 (48.5) | 26 (23.4) | 18 (46.2) | 19 (51.4) |  |
Age | 43.9 (12.5) | 44.3 (13.4) | 45.3 (10.9) | 43.2 (13.2) | 38.2 (10.5) | .061 |
School education | Â | Â | Â | Â | Â | .009* |
 high | 217 (57.0) | 126 (66.0) | 48 (43.2) | 25 (64.1) | 18 (48.6) |  |
 low | 138 (36.2) | 60 (30.9) | 52 (46.8) | 12 (30.8) | 14 (37.8) |  |
 not indicated | 26 (6.8) | 8 (4.1) | 11 (9.9) | 2 (5.1) | 5 (13.5) |  |
Country of birth | ||||||
 Germany | 223 (58.5) | 193 (99.5) | 19 (17.1) | 7 (17.9) | 4 (10.8) |  |
 Other country | 158 (41.5) | 1 (USA) | 92 (Turkey) | 30 (82.1) (3 Bulgaria, 1 Czech Republic, 1 Hungary, 1 Kosovo, 1 Latvia, 10 Poland, 1 Rumania, 8 Russia, 4 Serbia, 1 Ukraine, 1 former Yugoslavia) | 33 (89.2) (4 Iraq, 2 Iran, 1 Israel, 6 Lebanon, 2 Morocco, 1 Pakistan, 16 Syria, 1 Tunisia) |  |
Religious affiliation | Â | Â | Â | Â | Â | < .001* |
Yes | 230 (60.4) | 76 (39.2) | 97 (87.4) | 25 (64.1) | Â | Â |
No | 122 (32.0) | 94 (48.5) | 11 (9.9) | 13 (33.3) | Â | Â |
Not indicated | 29 (7.6) | 24 (12.4) | 3 (2.7) | 1 (2.6) | Â | Â |
Medication intake | Â | Â | Â | Â | Â | .597 |
 Yes | 328 (86.1) | 160 (82.5) | 98 (88.3) | 35 (89.7) | 35 (34.6) |  |
 No | 53(13.9) | 34 (17.5) | 13 (11.7) | 4 (10.3) | 2 (5.4) |  |
 Number of medications | 1.5 (0.7) | 1.3 (1.0) | 1.5 (0.9) | 1.7 (1.1) | 1.5(0.7) | .014* |
Type of medication | Â | Â | Â | Â | Â | .003* |
 Antidepressant | 269(70.6) | 109 (56.2) | 98 (88.3) | 31 (79.5) | 31 (83.8) |  |
 Neuroleptic | 207 (54.3) | 111 (57.2) | 50 (45.0) | 22 (56.4) | 24 (64.9) |  |
 Tranquillizer | 23 (6.9) | 13 (6.7) | 5 (4.5) | 4 (10.3) | 1 (2.7) |  |
 Mood stabilizer | 37 (7.1) | 20 (10.3) | 8 (7.2) | 9 (23.1) | 0 (0.0) |  |
 Antidementiva | 0(0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |  |
 Pain Medication | 12 (4.3) | 2 (1.0) | 8 (7.2) | 2 (5.1) | 0 (0.0) |  |
 Internal medication | 56 (14.7) | 35 (18.0) | 15 (13.5) | 3 (7.7) | 3 (8.1) |  |
 Substitution/ addiction treatment medication | 1 (0.3) | 1 (0.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) |  |
 Other | 12 (3.1) | 5 (2.6) | 5 (4.5) | 0 (0.0) | 2 (5.4) |  |
Inpatient stays (psychiatry) | Â | Â | Â | Â | Â | .005* |
 never | 132 (34.6) | 49 (25.3) | 55 (49.5) | 7 (17.9) | 21 (56.7) |  |
 seldom | 144 (37.8) | 76 (39.2) | 38 (34.2) | 20 (51.3) | 10 (27.0) |  |
 often | 92 (24.1) | 63 (31.5) | 14 (12.6) | 10 (25.6) | 5 (13.5) |  |
 not indicated | 13 (3.4) | 6 (3.1) | 4 (3.6) | 2 (5.1) | 1 (2.7) |  |
Symptom severity | ||||||
 SCL Somatization | 2.4 (1.2) | 2.0 (1.0) | 3.1 (1.3) | 2.4 (1.2) | 2.6 (1.0) | < .001* |
 SCL Depression | 2.8(1.1) | 2.6 (1.0) | 3.0 (1.1) | 3.2 (1.2) | 3.0 (1.0) | .184 |
 SCL Anxiety | 2.0 (1.0) | 1.7 (0.9) | 2.3 (1.1) | 1.9 (1.1) | 2.5 (1.2) | < .001* |
Diagnosis (ICD-10) | ||||||
 F0 | 8 (2.1) | 7 (3.6) | 1 (0.9) | 0 (0.0) | 0 (0.0) | < .001* |
 F1 | 85 (30.2) | 65 (33.5) | 9 (8.1) | 5 (12.8) | 6 (16.2) |  |
 F2 | 86 (30.6) | 51 (26.3) | 18 (16.2) | 9 (23.1) | 8 (21.6) |  |
 F3 | 164 (43.0) | 79 (40.7) | 49 (44.1) | 15 (38.5) | 21 (56.8) |  |
 F4 | 141 (37.0) | 50 (25.8) | 61 (55.0) | 15 (38.5) | 15 (40.5) |  |
 F5 | 7 (1.8) | 3 (1.5) | 2 (1.8) | 2 (5.1) | 0 (0.0) |  |
 F6 | 61 (16.0) | 46 (23.7) | 7 (6.3) | 8 (20.5) | 0 (0.0) |  |
 F7 | 7 (1.8) | 7 (3.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) |  |
 F8 | 0(0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |  |
 F9 | 2 (0.5 | 1 (0.5) | 1 (0.9) | 0 (0.0) | 0 (0.0) |  |